These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 8006339)

  • 1. Usefulness of thyrotropin-releasing hormone test, SMS 201-995, and bromocriptine in the diagnosis and treatment of gonadotropin-secreting pituitary adenomas.
    Blanco C; Lucas T; Alcañiz J; Davila N; Serrano P; Barcelò B; Estrada J
    J Endocrinol Invest; 1994 Feb; 17(2):99-104. PubMed ID: 8006339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine.
    Kwekkeboom DJ; de Jong FH; Lamberts SW
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1128-35. PubMed ID: 2542356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resolution of possible paradoxical responses of gonadotropins to thyrotropin-releasing hormone with bromocriptine therapy in a patient with follicle-stimulating hormone-secreting pituitary adenoma.
    Mercado-Asis LB; Yasuda K; Ishizawa M; Ishizuka T; Murayama M; Shimokawa K; Miura K
    Endocrinol Jpn; 1992 Aug; 39(4):401-6. PubMed ID: 1446655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas.
    Nobels FR; Kwekkeboom DJ; Coopmans W; Hoekstra R; De Herder WW; Bouillon R; Lamberts SW
    J Clin Endocrinol Metab; 1993 Sep; 77(3):784-9. PubMed ID: 7690365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of thyrotropin-releasing hormone on gonadotropin and free alpha-subunit secretion in patients with acromegaly and functionless pituitary tumors.
    Popovic V; Damjanovic S
    Thyroid; 1998 Oct; 8(10):935-9. PubMed ID: 9827662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of bromocriptine, thyrotropin-releasing hormone, and gonadotropin-releasing hormone on hormone secretion by gonadotropin-secreting pituitary adenomas in vivo and in vitro.
    Lamberts SW; Verleun T; Oosterom R; Hofland L; van Ginkel LA; Loeber JG; van Vroonhoven CC; Stefanko SZ; de Jong FH
    J Clin Endocrinol Metab; 1987 Mar; 64(3):524-30. PubMed ID: 3102540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of plasma gonadotropin levels and pituitary tumor size by treatment with bromocriptine in a patient with gonadotropinoma.
    Yamakita N; Komaki T; Murai T; Kawamura S
    Intern Med; 1999 Mar; 38(3):266-71. PubMed ID: 10337939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors.
    Klibanski A; Jameson JL; Biller BM; Crowley WF; Zervas NT; Rivier J; Vale WW; Bikkal H
    J Clin Endocrinol Metab; 1989 Jan; 68(1):81-6. PubMed ID: 2535852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotropin-releasing hormone agonists are unsuccessful in reducing tumoral gonadotropin secretion in two patients with gonadotropin-secreting pituitary adenomas.
    Sassolas G; Lejeune H; Trouillas J; Forest MG; Claustrat B; Lahlou N; Loras B
    J Clin Endocrinol Metab; 1988 Jul; 67(1):180-5. PubMed ID: 2967850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recognition of gonadotroph adenomas in women.
    Daneshdoost L; Gennarelli TA; Bashey HM; Savino PJ; Sergott RC; Bosley TM; Snyder PJ
    N Engl J Med; 1991 Feb; 324(9):589-94. PubMed ID: 1899470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of follicle-stimulating hormone (FSH) secretion in FSH-producing pituitary adenoma by bromocriptine.
    Berezin M; Olchovsky D; Pines A; Tadmor R; Lunenfeld B
    J Clin Endocrinol Metab; 1984 Dec; 59(6):1220-3. PubMed ID: 6436289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro.
    de Bruin TW; Kwekkeboom DJ; Van't Verlaat JW; Reubi JC; Krenning EP; Lamberts SW; Croughs RJ
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1310-7. PubMed ID: 1430093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal response of luteinizing hormone beta subunit to thyrotrophin-releasing hormone in patients with non-functioning pituitary adenoma.
    Gil-del-Alamo P; Pettersson KS; Saccomanno K; Spada A; Faglia G; Beck-Peccoz P
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):661-6. PubMed ID: 7828356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.
    Andersen M; Bjerre P; Schrøder HD; Edal A; Høilund-Carlsen PF; Pedersen PH; Hagen C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):23-30. PubMed ID: 11167922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of gonadotroph adenomas in men with clinically nonfunctioning adenomas by the luteinizing hormone beta subunit response to thyrotropin-releasing hormone.
    Daneshdoost L; Gennarelli TA; Bashey HM; Savino PJ; Sergott RC; Bosley TM; Snyder PJ
    J Clin Endocrinol Metab; 1993 Nov; 77(5):1352-5. PubMed ID: 8077332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma alpha-subunit levels during the treatment of pituitary adenomas with the somatostatin analog (SMS 201-995).
    Sassolas G; Serusclat P; Claustrat B; Trouillas J; Merabet S; Cohen R; Souquet JC
    Horm Res; 1988; 29(2-3):124-8. PubMed ID: 2456975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute effects of Parlodel-LAR and response to long-term treatment with bromocriptine in a patient with a follicle stimulating hormone-secreting pituitary adenoma.
    Abs R; Parizel PM; Beckers A
    J Endocrinol Invest; 1991 Feb; 14(2):135-8. PubMed ID: 1905737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responses to gonadotropin releasing hormone agonist and antagonist administration in patients with gonadotroph cell adenomas.
    Chanson P; Lahlou N; Warnet A; Roger M; Sassolas G; Lubetzi J; Schaison G; Bouchard P
    J Endocrinol Invest; 1994 Feb; 17(2):91-8. PubMed ID: 8006338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of luteinizing hormone secreting pituitary adenoma to a long-acting somatostatin analogue.
    Vos P; Croughs RJ; Thijssen JH; van 't Verlaat JW; van Ginkel LA
    Acta Endocrinol (Copenh); 1988 Aug; 118(4):587-90. PubMed ID: 2899940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.